BOTHELL, Wash., Jan. 13 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices that connect to electronic medical record (EMR) and hospital information systems, today announced a partnership with MEDENT, a leading provider of practice automation and EMR/EHR systems.
This new partnership provides 12,000 MEDENT physician users with the ability to connect their Quinton and Burdick ECG, cardiac stress test, and Holter systems with the MEDENT EMR/EHR systems. Cardiac Science, with an installed customer base of more than 65,000 diagnostic monitoring devices, can connect its devices with MEDENT systems for a smooth transfer of test results.
"Our customers want Cardiac Science's market-leading cardiac monitoring devices to connect with leading EMRs and EHRs," said Dave Marver, Cardiac Science president and chief executive officer. "This new partnership gives our large physician customer base the opportunity to choose MEDENT systems."
Cardiac Science's HeartCentrix connectivity solution gives physicians the ability to send data from their diagnostic and monitoring devices into the MEDENT EMR/EHR. The HeartCentrix solution can be installed with either a new MEDENT EMR/EHR implementation or into an existing MEDENT system.
"This partnership makes great business sense especially for the interoperability requirements of 'Meaningful Use,'" said MEDENT Vice President George Cuthbert. "This is the kind of seamless integration clients want for their practice: everything on the network working as one paperless system. This all greatly increases office efficiency and streamlines the process. Everything happens quicker with less labor."
Cardiac Science is a leader in diagnostic and cardiology devices, bringing ECG, Holter, cardiac stress, and automated external defibrillator products into the physician office. "With this new partnership, each existing and new Cardiac Science customer has another reason to confidently choose MEDENT for their EMR/EHR solution," Cuthbert added.
About Cardiac Science
Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress test treadmills and systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, vital signs monitors, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.
For updates and information on worldwide defibrillation and cardiac monitoring, find us on the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, Facebook at http://budurl.com/CSonFB, YouTube at http://www.youtube.com/user/CardiacScience.
MEDENT is a privately held corporation that is a recognized leader in the health care "Practice Management" automation market since 1968. As a company it is organized to deliver the long-term complete solution. MEDENT offers software, hardware, installation, training, ongoing support and supplies. MEDENT is headquartered in Auburn, NY, and has sales and service people located within each territory served. More information on MEDENT can be found at www.medent.com or by calling 315.255.1751.
This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's expectations regarding opportunities arising from its partnership with MEDENT and the resulting impact on operating results. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in Cardiac Science Corporation's Annual Report on Form 10-K for the year ended December 31, 2008, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
SOURCE Cardiac Science Corporation